Harish Shantharam
Chief Financial OfficerMr. Harish Shantharam, CFA, is Chief Financial Officer of ALX Oncology Holdings Inc. since January 21, 2025. He was Chief Financial Officer of CymaBay Therapeutics, Inc. from May 2023 until June 2024 and served as its Principal Accounting Officer since January 24, 2024 until June 2024. He joined the CymaBay Therapeutics, Inc. in May 2023. He has biotech experience leading financial functions with a very strong emphasis on setting strategy and building financial planning and accounting operations to prepare companies for commercial drug launch. Mr. Shantharam's career has been highlighted by a variety of progressive commercial planning, operations, FP&A and commercial finance roles, both domestically and globally. Mr. Shantharam was the Senior Finance Adviser to the CFO at Eikon Therapeutics. Prior to joining Eikon, he worked at Gilead, last serving as Vice President and Head of Global Commercial Finance. In this role, he supported revenue business and budget across North America, Europe, Asia and emerging markets. Prior to Gilead, Mr. Shantharam served in various roles of increasing responsibility driving forecasting, commercial analytics and business development at Amgen. Throughout his career, he has supported multiple product launches, leading financial and commercial operations. He holds an MBA in finance from UCLA Anderson School of Management and a graduate degree in Industrial Engineering from the University of Texas. He is also a CFA charter holder.
Positions
- Company NameALX Oncology Holdings Inc.Stock CodeALXOPositionChief Financial OfficerColleagues
- JWJason W. LettmannCEO & Director
- SGScott GarlandIndependent Chairman
- SWShelly WongSenior VP of Finance & Chief Accounting Officer
- BJBarbara J. KlenckeChief Medical Officer
- JEJeff E. KnightChief Development & Operating Officer
- RHRekha HemrajaniIndependent Director
- KTKeith T. FlahertyChair of the Scientific Advisory Board
- CHChris H. TakimotoIndependent Director
